System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Michele Guida is an expert in Oncology at Istituto Tumori Bari (Italy). As of October 2026, ScienceLeadR ranks Michele Guida in the top 1% of experts worldwide for Melanoma and Skin Neoplasms. Michele Guida has authored 208 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 7 of them ongoing. SLR score: 961 (community average: 125). How the SLR is computed.

LeadR Profile

Michele Guida Istituto Tumori Bari Italy
961 ScienceLeadR Reputation 961

Unlock

Register Login
Network Map

Oncology

Subspecialties: Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Istituto Tumori Bari

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 208

Citations

Citations: 4 148 1st author: 28 Last author: 36 Unique author: 1

Main journals

J Clin Oncol 23
Ann Oncol 17
J Transl Med 17
Eur J Cancer 12
Front Immunol 8

Best Journals

Ann Oncol 11
J Clin Oncol 7
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.
PMID 42683634 — cells, follow-up studies, carcinoma, squamous cell, skin diseases, therapeutics, cutaneous squamous cell carcinoma		J Dtsch Dermatol Ges20260
Clinical impact and therapeutic potential of tertiary lymphoid structures in melanoma.
PMID 42609770 — cells, melanoma, germinal center, neoplasms, tertiary lymphoid structures, immunotherapy, therapeutics		Front Immunol20260
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.
PMID 42550831 — melanoma, neoplasms, thymidine kinase, biomarkers, therapeutics, thymidine		Clin Cancer Res20260
Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study.
PMID 42467079 — melanoma, retrospective studies, neoplasms, immunotherapy, therapeutics		Cancer Immunol Immunother20260
Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma.
PMID 42382738 — cells, pregnancy, lung, carcinoma, squamous cell, neoplasms, immunotherapy, immune system diseases, nivolumab, diagnosis, therapeutics		Front Immunol20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 9
Phase 2 7
N/A 2
Phase 1 1
Phase 1/Phase 2 1

By status:

Completed 8
Recruiting 4
Active not recruiting 3
Unknown 3
Not yet recruiting 1
Terminated 1

By type:

Interventional 19
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 1
multicentricup10 19

Main Topics

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
L19IL2 L19TNF in patients with cutaneous squamous cell carcinoma
2025-523231-19-00 — cells, carcinoma, squamous cell, therapeutics, carcinoma, cutaneous squamous cell carcinoma		Phase 2Not yet recruiting2026
Phase II study of Roginolisib in UM patients
2024-514333-37-00 — melanoma, multiple chronic conditions, uveal melanoma		Phase 2Recruiting2025
Study aimed at testing the activity of a course of chemo immunotherapy with retifanlimab combined with platinum etoposide followed by surgery in patients with operable Merkel cell carcinoma
2024-516316-13-00 — cells, research design, merkel cells, immunotherapy, neoplasm metastasis, therapeutics, etoposide, carcinoma, merkel cell, carcinoma		Phase 2Active not recruiting2025
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
MELAFERT Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse
NCT07092670 — skin, comorbidity, fertility, pharmaceutical preparations, melanoma, neoplasms, disulfiram, nivolumab, therapeutics, skin neoplasms, women		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS